

Article type : Review Article

## Understanding the Immune Landscape in Atopic Dermatitis: The Era of Biologics and Emerging Therapeutic Approaches

Matthew Moyle, PhD<sup>1</sup>, Ferda Cevikbas, PhD<sup>2</sup>, Jamie L. Harden, PhD<sup>2</sup>, Emma Guttman-Yassky, MD, PhD<sup>3</sup>

<sup>1</sup>Aravax, Melbourne, Victoria, Australia (independent participation); <sup>2</sup>Dermira Inc., Menlo Park, CA, USA; <sup>3</sup>Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, USA 10029, [emma.guttman@mountsinai.org](mailto:emma.guttman@mountsinai.org)

### ABSTRACT

Atopic dermatitis (AD) is a chronic, systemic, inflammatory disease that affects the skin and is characterized by persistent itch and marked redness. AD is associated with an increased risk of skin infections and a reduced quality of life. Most AD treatment options to date were not designed to selectively target disease-causing pathways that have been established for this indication. Topical therapies have limited efficacy in moderate-to-severe disease, and systemic agents such as corticosteroids and immunosuppressants present with tolerability issues. Advances in the understanding of AD pathobiology have made possible a new generation of more disease-specific AD therapies. AD is characterized by the inappropriate activation of type 2 T helper (Th2) cells and type 2 innate lymphoid (ILC2) cells, with a predominant increase in type 2 cytokines in the skin, including interleukin (IL)-13 and IL-4. Both cytokines are implicated in tissue inflammation and epidermal barrier dysfunction, and monoclonal antibodies targeting each of these interleukins or their receptors are in clinical development in AD. In March of 2017, dupilumab, a human anti-IL-4R $\alpha$  antibody became the first biologic to receive FDA approval for the treatment of moderate-to-severe AD. The anti-IL-13 monoclonal antibodies lebrikizumab and tralokinumab, which bind different IL-13 epitopes with potentially different effects, are currently in advanced-stage trials. Here, we briefly review the underlying pathobiology of AD, the scientific basis for current AD targets, and summarize current clinical studies of these agents, including new research to develop both predictive and response biomarkers to further advance AD therapy in the era of precision medicine.

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/exd.13911

This article is protected by copyright. All rights reserved.

## INTRODUCTION

Atopic dermatitis (AD), the most common inflammatory skin disease, is characterized by chronic, systemic inflammation, early age of onset, persistent itch, marked redness, cracking, and/or dryness of the skin, and a relapsing course.<sup>1-3</sup> Prevalence of AD in the United States ranges from approximately 5% to 10% in adults and 10% to 13% in children, with moderate-to-severe disease occurring in about half of the adults (mean 54% [range 42-73%]) and a third of the children (33%).<sup>2,4-20</sup>

Moderate-to-severe AD is viewed as a systemic disease with increases in T and B cells in the circulation as well as in skin tissue.<sup>21-26</sup> The systemic nature of the disease is also reflected in associated co-morbidities, including cardiovascular, neuropsychiatric, and malignant diseases, among others.<sup>24,26-32</sup>

Patients with AD often suffer from significantly reduced quality of life, with impairments in both social and physical functioning.<sup>3</sup> Patients with AD report occupational impairments, reduced productivity at school and work, interpersonal problems (eg, social isolation, relationship issues), and reduced self-esteem.<sup>33,34</sup> For many, severe chronic itch impacts sleep and productivity.<sup>34</sup> Mental health disorders, including anxiety, depression, and attention-deficit/hyperactivity disorder, are also more common in both children and adults with AD.<sup>35,36</sup> In addition, altered immune responses render patients with AD at increased risk for bacterial, viral, and fungal skin infections, particularly by *Staphylococcus aureus* and herpes simplex type 1 virus.<sup>29-31,37,38</sup>

Conventional treatment approaches for AD, which include topical therapies (eg, emollients, corticosteroids, calcineurin inhibitors), phototherapy, and systemic agents, highlight the unmet need for safe and more durable therapies.<sup>39-41</sup> The Food and Drug Administration (FDA) has approved three topical treatments for AD, including pimecrolimus and tacrolimus (topical calcineurin inhibitors), and crisaborole ointment (topical phosphodiesterase-4 inhibitor). Although topical therapies are commonly used in treating mild disease, a number of disadvantages have been recognized: they do not address systemic inflammation, patients often relapse, and the therapies have limited efficacy in moderate-to-severe disease, where the affected body surface area is much greater.<sup>42</sup> While systemic therapies, including corticosteroids and immunosuppressants (eg, cyclosporine A, methotrexate, azathioprine) have demonstrated efficacy, their long-term use is limited by poor adverse event and/or tolerability profiles.<sup>33,42</sup> Perhaps most important, conventional treatments are not specific in their targeting of the underlying disease biology.<sup>40,41</sup>

Improved understanding of AD disease pathophysiology has facilitated development of targeted therapeutic approaches that block disease-specific cytokines or receptors using antibodies. These disease-focused treatment approaches have demonstrated efficacy while also improving safety, leading to the potential for long-term care. One of these, dupilumab, has been approved (March 2017)

by the FDA for the treatment of adults with moderate-to-severe AD. This review summarizes key AD pathophysiologic mechanisms and describes emerging therapeutic agents, with emphasis on biologics and the potential benefits they may bring to the clinic.

## **AD PATHOPHYSIOLOGY: COMPLEX DYSREGULATION OF IMMUNE PATHWAYS**

### **The Aberrant Immune Landscape and Biomarkers of Disease**

Advances in the understanding of AD pathophysiology have demonstrated the role of systemic inflammation and immune dysfunction in mediating disease. Generally, the clinical presentation of acute and chronic eczematous skin lesions, respectively, differs in color (bright versus dull red), thickness (flatter versus thicker), and spongiosis (marked versus minimal) of the dermis.<sup>2,43,44</sup> AD is characterized by aberrant and excessive Th2 cell and ILC2 activation, with robust expression of type 2 cytokines, including interleukin (IL)-4, IL-5, IL-13, and IL-31 (**Table 1**).<sup>45-48</sup> While activation of a type 2 immune response is common to all patients with AD, variable activation of other cytokines (particularly IL-22, but also IL-17, IL-9, and IFN $\gamma$ ) is additionally seen, contributing to the diversity of clinical AD subtypes.<sup>49-53</sup> Analyses of transcriptomes from intra-individual acute and chronic skin lesions, as well as non-lesional skin from adult AD patients, indicates progressive changes in type 2 and type 22 (eg, IL-22) pathway activation from acute to chronic disease, with induction of type 1 cytokine responses (eg, IFN $\gamma$ ) only in chronic lesions.<sup>44</sup> Studies in pediatric AD also showed a pattern of excessive type 2 inflammation, but with higher activation of type 9 and type 17 effectors at disease initiation.<sup>51</sup>

In acute AD lesions, the disease is characterized by significant increases in type 2- (eg, IL-4, IL-13, IL-31) and type 22-specific cytokines and corresponding downstream effects (**Table 1 and Table 2**).<sup>44,47</sup> As key type 2 pathway mediators, IL-4 and IL-13 have multifaceted implications in AD pathophysiology, including propagation of inflammation, epidermal barrier dysfunction, and itch.<sup>33,42</sup> Serum levels of IL-13 positively correlate with levels of the itch-promoting cytokine IL-31, which in turn have been correlated with disease severity.<sup>54-57</sup> Of note, IL-22 and the type 17-specific cytokine, IL-17, upregulate expression of certain S100 epidermal differentiation proteins including S100A7, S100A8, and S100A9.<sup>58</sup> These S100 proteins, along with IL-31 and IL-22, showed significant upregulation between non-lesional skin and acute lesions, with further increases in chronic lesions.<sup>44</sup> In chronic lesions, type 2 and type 22-specific inflammation is generally intensified compared with acute lesions, as indicated by increased expression of corresponding cytokines (eg, IL-13 and IL-31 [type 2], IL-22 [type 22])).<sup>44</sup> Data are mixed for gene expression changes of IL-4 in chronic lesions, with some reports of decreased expression<sup>44</sup> and others reporting an increase.<sup>33</sup>

It is well established that epidermal barrier disruption contributes to AD pathophysiology, and marked skin changes are associated with lesion development (**Table 1**).<sup>59,60</sup> Epidermal thickness and proliferation, assessed via keratin 16 (K16) and Ki67 expression, are increased in acute AD compared with non-lesional skin; these changes are significantly increased further in chronic versus acute AD lesions.<sup>44</sup> Terminal markers of epidermal differentiation, including loricrin, periplakin, and filaggrin, as well as tight junctions and lipids, are suppressed in chronic versus acute AD.<sup>47,61-65</sup> Lastly, immune cell infiltrates, including T cells, DCs (including mature and inflammatory dendritic epidermal cells [IDECs]), and myeloid cells, are significantly increased in acute versus non-lesional skin, with yet greater increases in chronic lesions.<sup>44</sup>

Transcriptomic and histologic profiling of lesional and non-lesional AD skin has elucidated differences in the inflammatory skin phenotypes that exist in AD (**Table 1**).<sup>28,47</sup> Generally, changes observed in lesional skin are also present but less marked in non-lesional skin. Both are characterized by cellular and molecular abnormalities, including markers of epidermal hyperplasia, cellular infiltrates, and increased inflammatory mediators compared with skin from individuals without AD.<sup>27,28</sup> The inflammatory changes evident in non-lesional skin may reflect, in part, the systemic nature of AD.<sup>21,23-25,27,45</sup>

While AD chronicity can further be characterized by a number of biomarkers identified in skin (eg, IL-4, IL-13, IL-31, epidermal thickness),<sup>44,47</sup> a panel of serum biomarkers has also been shown to be increased in moderate-to-severe AD patients compared with healthy controls, speaking not only to the diagnostic utility of this approach, but also to the systemic nature of AD.<sup>3,24,32,45,66</sup> Given the intrusive nature of skin biopsies, serum inflammatory biomarkers may be a more practical alternative to assess severity, particularly in pediatric patients.<sup>45</sup>

## **IL-4 and IL-13: Key Type 2 Immune Mediators**

### ***Receptors and Downstream Signaling Molecules***

While multiple molecules have been implicated in AD, studies in mice and humans have elucidated a central role for IL-4 and IL-13 (**Table 2**).<sup>33</sup> IL-4- and IL-13-mediated signaling occurs via a shared heterodimeric receptor that comprises IL-13R $\alpha$ 1 and IL-4R $\alpha$ , also known as the type 2 IL-4 receptor, which is expressed on most cell types (**Figure 1**).<sup>33,67</sup> Cytokine-mediated heterodimerization of the receptor subunits triggers subsequent downstream signaling via JAK1-mediated phosphorylation of the transcription factor STAT6, resulting in an overlap in function of IL-4 and IL-13, which has been well described in the literature.<sup>33,67</sup> IL-4 also signals through the type 1 IL-4 receptor that is made up of IL-4R $\alpha$  and the common gamma-chain, which is expressed chiefly on hematopoietic cells (eg, T cells and B cells).

### ***Biological Responses to IL-4 and IL-13***

Both IL-4 and IL-13 stimulate immunoglobulin E (IgE) production from plasma cells, B cell and plasma cell differentiation, and Th2 cell development/differentiation, among other effects (**Table 2**).<sup>33</sup> They have both been implicated in tissue inflammation in mouse models of AD.<sup>68,69</sup> Additionally, both contribute to epidermal barrier dysfunction and keratinocyte damage in AD. Keratinocytes cultured in vitro in the presence of IL-4 and IL-13 had significantly reduced filaggrin expression irrespective of filaggrin mutation status.<sup>70</sup> Accordingly, filaggrin expression is significantly reduced in acute AD lesions compared with normal skin.<sup>70</sup> In addition to filaggrin, loricrin and involucrin are important for formation and integrity of the epidermal barrier,<sup>33</sup> and IL-4 and IL-13 downregulated loricrin and involucrin at the gene and protein level in primary keratinocytes.<sup>71</sup> Type 2 pathway activation can also trigger tissue fibrosis in AD through recruitment of fibrocytes to inflamed skin lesions.<sup>72</sup> IL-13-mediated tissue inflammation promotes fibrotic skin remodeling through the recruitment of fibroblasts and subsequent deposition of collagen.<sup>72</sup> Type 2 cytokines also directly induce activation of sensory neurons in murine models and in human dorsal root ganglia, eliciting chronic itch.<sup>73,74</sup>

Given the pleiotropic role of IL-4 and IL-13 in AD pathophysiology, several therapeutic approaches aimed at inhibiting these cytokines have been explored; these are described in detail in the next section. While gene expression studies in AD patients have suggested that IL-13 may be of greater pathophysiological importance,<sup>75</sup> ongoing and future clinical trials will help differentiate which of these two cytokines plays a more central role in this disease.

### **THE ERA OF BIOLOGICS AND EMERGING THERAPEUTIC APPROACHES**

Topical therapies have improved AD in mild cases but are not effective in patients with more severe disease, and may be difficult to apply for patients with large amounts of affected body surface area.<sup>42</sup> While systemic immunosuppressants (eg, corticosteroids, cyclosporine A, methotrexate) have demonstrated efficacy, they cannot be used long-term due to poor tolerability.<sup>42</sup> For example, common side effects of corticosteroids include glucose intolerance, headaches, and depression; those of cyclosporin A include headaches, nephrotoxicity, and hypertension; and those of methotrexate are anemia, leukopenia, and hepatotoxicity.<sup>33</sup> Of these therapies, none are FDA approved for the treatment of AD, though cyclosporine A is approved in Europe. Increased understanding of AD immunopathology had sparked development of targeted therapeutic approaches, and biologics have become a focus of research for AD treatments.

### Targeting IL-4 and IL-13

Given the multifaceted and central role of IL-4 and IL-13 in AD pathophysiology, a number of biologics targeting either IL-13 or both IL-4 and IL-13 pathways are under development (**Figure 2**). The essential role of the type 2 axis was validated by the clinical success of dupilumab, a fully human, IgG4 $\kappa$  monoclonal antibody targeting IL-4R $\alpha$  and the first biologic approved for AD.<sup>76-78</sup> By antagonizing IL-4R $\alpha$ , dupilumab blocks both IL-4- and IL-13-mediated signaling through the type 2 receptor, which requires heterodimerization of IL-4R $\alpha$  and IL-13R $\alpha$ 1. Dupilumab also inhibits IL-4 signaling via the type 1 receptor.

Two IL-13-targeting antibodies, tralokinumab and lebrikizumab, are the most advanced IL-13-specific biologics in clinical development for the treatment of AD (**Figure 1**). Tralokinumab, an IgG4 $\lambda$  anti-IL-13 monoclonal antibody derived from a human phage display library, prevents IL-13 from binding to both IL-13R $\alpha$ 1 and IL-13R $\alpha$ 2.<sup>79</sup> The latter receptor has a short cytoplasmic tail and no known signaling motifs, and is thought to have an anti-inflammatory, decoy function via internalization of excess IL-13.<sup>80,81</sup> In this way, tralokinumab prevents both IL-13-mediated signaling downstream of IL-4R $\alpha$ /IL-13R $\alpha$ 1 heterodimerization (type 2 receptor), but it may also interfere with endogenous regulation of IL-13 that is mediated by IL-13R $\alpha$ 2. Loss of function of the IL-13 decoy receptor was shown to be deleterious in a mouse model of cutaneous inflammation.<sup>86</sup> Lebrikizumab is a humanized, IgG4 $\kappa$  monoclonal antibody that also binds soluble IL-13 with high affinity, but at a different epitope compared with tralokinumab.<sup>82</sup> Lebrikizumab-bound IL-13 can still bind to its cell surface receptors, but the biologic prevents IL-4R $\alpha$ /IL-13R $\alpha$ 1 heterodimerization (type 2 receptor) and downstream signaling. It does not, however, prevent IL-13 binding to the IL-13R $\alpha$ 2 decoy receptor. Although direct comparison of the biological differences between tralokinumab and lebrikizumab with respect to IL-13 modulation has not been done to date, a mechanistic pharmacokinetic/pharmacodynamic (PK/PD) model was generated to understand the IL-13 profiles of two other anti-human IL-13 monoclonal antibodies evaluated in separate phase 1 trials (ie, IMA-638 [NCT00339872; mild-to-moderate asthma] and IMA-026 [NCT00517348; healthy subjects]).<sup>83</sup> The two antibodies interfere with IL-13-mediated signaling by different mechanisms. IMA-638 prevents access of the pre-bound IL-13/IL-13R $\alpha$ 1 complex to the receptor signaling subunit IL-4R $\alpha$ , while IMA-026 interferes with IL-13 binding to IL-13R $\alpha$ 1. Moreover, IMA-026 blocks binding of IL-13 to IL-13R $\alpha$ 2 and IMA-638 does not, so these antibodies may be considered surrogates for tralokinumab and lebrikizumab, respectively. While the PK profiles of IMA-638 and IMA-026 were similar, the total IL-13 (free and drug bound) profiles differed; specifically, the significant dose-dependent accumulation of total IL-13 observed with IMA-026 treatment was not evident following treatment with IMA-638. This finding suggests that prevention of IL-13 binding to the decoy receptor may result in heightened levels of systemic IL-13. The PK/PD model also predicted greater and more

sustained inhibition of IL-13 with IMA-638 compared with IMA-026 when administered at equivalent doses. Although caution should be exercised when comparing IMA-026 and IMA-638 with tralokinumab and lebrikizumab, respectively, this study highlights differences in the IL-13 inhibitory potential between these similar antibodies with slightly different mechanisms of action. Further preclinical and mechanism of action data for tralokinumab and lebrikizumab are warranted to clearly dissect biological differences.

All three of these biologics (ie, dupilumab, lebrikizumab, and tralokinumab) have been evaluated in monotherapy and/or combination therapy studies in moderate-to-severe AD (tralokinumab, combination therapy only). Differences in study design (most notably trial duration, population size, whether TCS run-in was allowed and the dosing frequencies used), limit the ability to make direct comparisons among findings (**Table 3**).<sup>76-78,84,85</sup> Importantly, a systematic review of published preclinical and clinical studies between January 2006 and October 2016 demonstrated no increase in the risk of serious safety signals (eg, infection, malignancy, cardiovascular events) with anti-IL-13 alone or in combination with IL-4 via inhibition of IL-4R $\alpha$ .<sup>86</sup> While long-term safety studies are necessary, these therapies generally appear to be safe and effective for the treatment of moderate-to-severe AD.<sup>33,87</sup> The relative clinical utility and potential individual advantages among these biologics remain to be determined, as their differences with respect to specific mechanistic targets, bioavailability, half-life, and dosing frequency (among other attributes) have the potential to impact clinical experience.

### **Other Biologics in Development**

As AD is characterized by dysfunction in multiple immune pathways (types 1, 2, 17, and 22), a number of biologics in development target key effectors (eg, cytokines, cytokine receptors) of these biological responses (**Table 4**). While some of the novel biologics have shown promising clinical data for the treatment of AD, additional prospective studies are warranted to confirm efficacy and safety.

### **Small Molecule Inhibitors**

Beyond biologics, several small molecule inhibitors are in various stages of clinical development. For example, promising results with the oral JAK1 inhibitor upadacitinib were reported from a phase 2b, 88-week, randomized controlled trial (NCT02925117), which prompted FDA breakthrough therapy for adults with moderate-to-severe AD, in January 2018. Several phase 3, randomized, controlled clinical trials are planned in adolescent and adults (ie, 12-75 years) with moderate-to-severe AD, including two replicate studies of once-daily upadacitinib monotherapy (NCT03569293 and NCT03607422) and one combination study with topical corticosteroids (NCT03568318). In addition, phase 2 results with the once-daily, oral JAK1/JAK2 inhibitor baricitinib<sup>88</sup> (NCT02576938) have led to multiple phase 3 studies in adults with moderate-to-severe AD. These include replicate, 16-week

randomized controlled trials (BREEZE-AD1 [NCT03435081] and BREEZE-AD2 [NCT03334422]), a 52-week, long-term safety and efficacy study (BREEZE-AD3 [NCT03334435]), a 16-week, randomized controlled trial (BREEZE-AD5 [NCT03334396]) with 116-week open-label extension (BREEZE-AD6 [NCT03559270]), and a randomized controlled trial in adults who had inadequate response to, intolerance to, or were contraindicated for cyclosporine (BREEZE-AD4 [NCT03428100]). Lastly, PF-04965842, an oral JAK1 inhibitor, has completed a phase 2 study (NCT02780167) and is under investigation in phase 3 trials in patients aged 12 years and older with moderate-to-severe AD. Studies include replicate, 12-week, randomized controlled trials (JADE Mono-1 [NCT03349060] and JADE Mono-2 [NCT03575871]) and a 96-week, long-term extension study (JADE EXTEND [NCT03422822]).

Another set of small molecule inhibitors, which have been investigated for the treatment of AD, include those targeting phosphodiesterase-4 (PDE-4), an enzyme involved in chronic inflammatory pathways. Inhibition of PDE-4 increases levels of cyclic adenosine monophosphate (cAMP), which mediates downstream events culminating in the inhibition of inflammatory cytokine secretion (eg, IL-12, IL-17, IL-23, IFN $\gamma$ ).<sup>89</sup> Though several PDE-4 inhibitors (eg, apremilast, roflumilast) have not had clinical success to date, topical crisaborole was FDA approved in December 2016 for the treatment of mild-to-moderate AD in patients aged 2 years and older.<sup>90</sup>

### **Developing and Differentiating Therapies: Biomarkers of Treatment Response**

AD is a heterogeneous disease, both clinically and biologically, as several subtypes of AD have been recognized (ie, intrinsic/extrinsic, adult/pediatric, ethnic origin), which differ in prevalence and clinical features.<sup>49,53,91-95</sup> Biomarkers may help clarify AD diagnosis by defining endotypes, subsets of patients with common underlying mechanisms of disease.<sup>96</sup> Biomarkers could be useful for screening those at high risk of AD before clinical disease appears and might aid in the early diagnosis of AD.<sup>97</sup> Beyond its diagnostic potential, the development of biomarkers in AD will allow more accurate assessment of disease severity than current methods, which require subjective inputs and for which there are currently many different composite indices. Studies of biomarkers for AD severity have recently begun to appear, but to date validated biomarkers for AD severity are lacking.<sup>98,99</sup> The availability of such biomarkers would allow quicker and more accurate assessment of treatment effects, the quantification of subtle clinical effects in patients where the disease phenotype is less visually evident, and, by providing a common standard, would minimize some of the uncertainties in cross-trial comparisons.<sup>100</sup> The integration of biomarker data in AD drug development, as was done in psoriasis, could help identify effective treatment approaches and drive promising agents forward.<sup>47,101,102</sup>

Importantly, biomarkers predictive of treatment response would allow for improved patient selection and stratification for targeted agents in AD.<sup>47</sup> An example of the promise of this approach has been reported for lebrikizumab in asthma, where the mean increase in forced expiratory volume (FEV<sub>1</sub>) relative to placebo was considerably higher in adults with high levels of periostin, a protein induced by the type 2 cytokines IL-4 and IL-13.<sup>103</sup> The identification of validated predictive AD biomarkers could thus allow for a more personalized treatment approach that minimizes the risk of clinical failure of targeted agents in unselected patient populations and the expense of novel agents in patients for whom they provide no benefit. In this regard, biomarkers may be central to future advancements in AD.<sup>24,47</sup> With this in mind, predictive biomarkers for therapeutic responses were defined in AD patients treated with anti-IL-22 therapy, perhaps opening the door to a predictive medicine approach in AD and beyond.<sup>110,111</sup> In this way, the implications of disease heterogeneity on treatment responses may be attenuated as patients could ultimately receive personalized therapeutic approaches to treat their AD.

### CLINICAL PERSPECTIVE

The importance of IL-4R $\alpha$  in disease pathobiology, and therefore IL-4 and IL-13 which utilize the receptor for signaling, was validated by the demonstration of clinical efficacy for dupilumab in patients with AD.<sup>45,76,77,112</sup> Yet, debate continues regarding which of these cytokines is most central to pathophysiology, or if blocking both is required for a clinical response. Ongoing and future clinical and research studies will help to definitively address this question. Although further studies are warranted, the initial success of lebrikizumab and tralokinumab suggest that IL-13 blockade may be sufficient for achieving responses in AD patients.

The inclusion of biomarker analyses in clinical trial designs may improve outcome assessments and comparison of therapeutics, particularly biologics. One such option may be a predictive serum biomarker signature that represents a reliable and objective measure of disease severity not vulnerable to intra- or interrater variability.<sup>24,25,32,113</sup> Skin and serum biomarkers, which would ideally have utility in the near future, may be used to predict therapeutic responses to various treatments.<sup>110</sup> Furthermore, defining the disease remnant after successful treatment response may provide higher resolution in comparing treatment responses and identify drugs that are best at minimizing the “molecular scar” after treatment.<sup>109,114</sup> Improved understanding of the immune landscape in AD has stimulated the development of promising, novel therapeutic agents. Future incorporation of biomarkers in treatment response predictions may help transform the treatment paradigm of AD and the ability to generate meaningful and lasting responses, including cures.

## ACKNOWLEDGMENTS

Medical writing support for this manuscript was provided by Prescott Medical Communications Group (Chicago, IL), with financial support from Dermira, Inc.

## CONFLICTS OF INTEREST

**MM:** Consultant for Dermira

**FC:** Employee of Dermira

**JLH:** Employee of Dermira

**EG:** Consultant for AbbVie, Anacor, Celgene, Celsus Therapeutics, Dermira, Galderma, Glenmark, Janssen Biotech, LEO Pharmaceuticals MedImmune, Novartis, Pfizer, Regeneron, Sanofi, Stiefel/GlaxoSmithKline, Vitae, Mitsubishi Tanabe, Eli Lilly, Asana Biosciences, and Kiowa Kirin; investigator for Celgene, Glenmark, Leo Pharmaceuticals, MedImmune, Regeneron, Eli Lilly; advisory boards for Celgene, Celsus Therapeutics, Dermira, Galderma, Glenmark, MedImmune, Novartis, Pfizer, Regeneron, Sanofi, Stiefel/GlaxoSmithKline, Vitae, and Asana Biosciences

## AUTHOR CONTRIBUTIONS

**MM, FC, JLH,** and **EG** participated in gathering and analysis of the data, writing and revising the paper, and have all read and approved the final manuscript.

## REFERENCES

1. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. *J Am Acad Dermatol*. 2014;70(2):338-351.
2. Bieber T. Atopic dermatitis. *Ann Dermatol*. 2010;22(2):125-137.
3. Brunner PM, Silverberg JI, Guttman-Yassky E, et al. Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder. *J Invest Dermatol*. 2017;137(1):18-25.
4. Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. *Allergy*. 2018;73(6):1284-1293.
5. Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. *J Allergy Clin Immunol*. 2013;132(5):1132-1138.
6. Silverberg JI, Garg NK, Paller AS, Fishbein AB, Zee PC. Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. *J Invest Dermatol*. 2015;135(1):56-66.
7. Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient-burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. *Ann Allergy Asthma Immunol*. 2018.
8. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. *J Invest Dermatol*. 2011;131(1):67-73.

9. Fuxench ZC OP, Boguniewicz M, et al. Prevalence and impact of disease severity on health-related quality of life in adult patients with atopic dermatitis. *J Am Acad Dermatol*. 2018;79(3, Supplement 1):AB227.
10. Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. *Dermatitis*. 2014;25(3):107-114.
11. Silverberg JI, Simpson EL. Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization. *Pediatr Allergy Immunol*. 2013;24(5):476-486.
12. Arkwright PD, Motala C, Subramanian H, et al. Management of difficult-to-treat atopic dermatitis. *J Allergy Clin Immunol Pract*. 2013;1(2):142-151.
13. Asher MI, Montefort S, Bjorksten B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. *Lancet*. 2006;368(9537):733-743.
14. Hanifin JM, Reed ML, Eczema P, Impact Working G. A population-based survey of eczema prevalence in the United States. *Dermatitis*. 2007;18(2):82-91.
15. Hua T, Silverberg JI. Atopic dermatitis in US adults - epidemiology, association with marital status and atopy. *Ann Allergy Asthma Immunol*. 2018.
16. Lee HH, Patel KR, Singam V, Rastogi S, Silverberg JI. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. *J Am Acad Dermatol*. 2018.
17. Odhiambo JA, Williams HC, Clayton TO, Robertson CF, Asher MI, Group IPTS. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. *J Allergy Clin Immunol*. 2009;124(6):1251-1258 e1223.
18. Peroni DG, Piacentini GL, Bodini A, Rigotti E, Pigozzi R, Boner AL. Prevalence and risk factors for atopic dermatitis in preschool children. *Br J Dermatol*. 2008;158(3):539-543.
19. Whiteley J, Emir B, Seitzman R, Makinson G. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. *Curr Med Res Opin*. 2016;1-7.
20. Willemsen MG, van Valburg RW, Dirven-Meijer PC, Oranje AP, van der Wouden JC, Moed H. Determining the severity of atopic dermatitis in children presenting in general practice: an easy and fast method. *Dermatol Res Pract*. 2009;2009:357046.
21. Czarnowicki T, Gonzalez J, Shemer A, et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. *J Allergy Clin Immunol*. 2015;136(1):104-115.e107.
22. Czarnowicki T, Malajian D, Shemer A, et al. Skin-homing and systemic T-cell subsets show higher activation in atopic dermatitis versus psoriasis. *J Allergy Clin Immunol*. 2015;136(1):208-211.
23. Czarnowicki T, Esaki H, Gonzalez J, et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. *J Allergy Clin Immunol*. 2015;136(4):941-951.e943.
24. Ungar B, Garcet S, Gonzalez J, et al. An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease. *J Invest Dermatol*. 2017;137(3):603-613.
25. Brunner PM, Suarez-Farinas M, He H, et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. *Sci Rep*. 2017;7(1):8707.
26. Czarnowicki T, Gonzalez J, Bonifacio KM, et al. Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. *J Allergy Clin Immunol*. 2016;137(1):118-129.e115.
27. Brunner PM, Emerson RO, Tipton C, et al. Nonlesional atopic dermatitis skin shares similar T-cell clones with lesional tissues. *Allergy*. 2017;72(12):2017-2025.
28. Suarez-Farinas M, Tintle SJ, Shemer A, et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. *J Allergy Clin Immunol*. 2011;127(4):954-964.e951-954.

29. Silverwood RJ, Forbes HJ, Abuabara K, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. *BMJ*. 2018;361:k1786.
30. Silverberg JI. Association between adult atopic dermatitis, cardiovascular disease, and increased heart attacks in three population-based studies. *Allergy*. 2015;70(10):1300-1308.
31. Zhang A, Silverberg JI. Association of atopic dermatitis with being overweight and obese: a systematic review and metaanalysis. *J Am Acad Dermatol*. 2015;72(4):606-616.e604.
32. Wen HC, Czarnowicki T, Noda S, et al. Serum from Asian patients with atopic dermatitis is characterized by TH2/TH22 activation, which is highly correlated with nonlesional skin measures. *J Allergy Clin Immunol*. 2018;142(1):324-328.e311.
33. Silverberg JI, Kantor R. The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis. *Dermatol Clin*. 2017;35(3):327-334.
34. Drucker AM, Wang AR, Li WQ, Severson E, Block JK, Qureshi AA. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. *J Invest Dermatol*. 2017;137(1):26-30.
35. Strom MA, Fishbein AB, Paller AS, Silverberg JI. Association between atopic dermatitis and attention deficit hyperactivity disorder in U.S. children and adults. *Br J Dermatol*. 2016;175(5):920-929.
36. Yaghmaie P, Koudelka CW, Simpson EL. Mental health comorbidity in patients with atopic dermatitis. *J Allergy Clin Immunol*. 2013;131(2):428-433.
37. Leyden JJ, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. *Br J Dermatol*. 1974;90(5):525-530.
38. Baker BS. The role of microorganisms in atopic dermatitis. *Clin Exp Immunol*. 2006;144(1):1-9.
39. Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012. *J Allergy Clin Immunol*. 2013;131(2):295-299.e291-227.
40. Akdis CA, Akdis M, Bieber T, et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. *J Allergy Clin Immunol*. 2006;118(1):152-169.
41. Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. *J Eur Acad Dermatol Venereol*. 2012;26(9):1176-1193.
42. Silverberg JI. Atopic dermatitis treatment: Current state of the art and emerging therapies. *Allergy Asthma Proc*. 2017;38(4):243-249.
43. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. *J Clin Invest*. 2004;113(5):651-657.
44. Gittler JK, Shemer A, Suarez-Farinas M, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. *J Allergy Clin Immunol*. 2012;130(6):1344-1354.
45. Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. *J Allergy Clin Immunol*. 2017;139(4S):S65-S76.
46. Lund S, Walford HH, Doherty TA. Type 2 Innate Lymphoid Cells in Allergic Disease. *Curr Immunol Rev*. 2013;9(4):214-221.
47. Mansouri Y, Guttman-Yassky E. Immune Pathways in Atopic Dermatitis, and Definition of Biomarkers through Broad and Targeted Therapeutics. *J Clin Med*. 2015;4(5):858-873.
48. Roediger B, Kyle R, Yip KH, et al. Cutaneous immunosurveillance and regulation of inflammation by group 2 innate lymphoid cells. *Nat Immunol*. 2013;14(6):564-573.
49. Suarez-Farinas M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. *J Allergy Clin Immunol*. 2013;132(2):361-370.
50. Noda S, Suarez-Farinas M, Ungar B, et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. *J Allergy Clin Immunol*. 2015;136(5):1254-1264.

51. Esaki H, Brunner PM, Renert-Yuval Y, et al. Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. *J Allergy Clin Immunol.* 2016;138(6):1639-1651.
52. Cole C, Kroboth K, Schurch NJ, et al. Filaggrin-stratified transcriptomic analysis of pediatric skin identifies mechanistic pathways in patients with atopic dermatitis. *J Allergy Clin Immunol.* 2014;134(1):82-91.
53. Akdis CA, Akdis M. Immunological differences between intrinsic and extrinsic types of atopic dermatitis. *Clin Exp Allergy.* 2003;33(12):1618-1621.
54. Raap U, Weissmantel S, Gehring M, Eisenberg AM, Kapp A, Folster-Holst R. IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis. *Pediatr Allergy Immunol.* 2012;23(3):285-288.
55. Raap U, Wichmann K, Bruder M, et al. Correlation of IL-31 serum levels with severity of atopic dermatitis. *J Allergy Clin Immunol.* 2008;122(2):421-423.
56. Ezzat MH, Hasan ZE, Shaheen KY. Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring. *J Eur Acad Dermatol Venereol.* 2011;25(3):334-339.
57. Trier AM, Kim BS. Cytokine modulation of atopic itch. *Curr Opin Immunol.* 2018;54:7-12.
58. Boniface K, Bernard FX, Garcia M, Gurney AL, Lecron JC, Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. *J Immunol.* 2005;174(6):3695-3702.
59. Cork MJ, Robinson DA, Vasilopoulos Y, et al. New perspectives on epidermal barrier dysfunction in atopic dermatitis: gene-environment interactions. *J Allergy Clin Immunol.* 2006;118(1):3-21; quiz 22-23.
60. Palmer CN, Irvine AD, Terron-Kwiatkowski A, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. *Nat Genet.* 2006;38(4):441-446.
61. Esaki H, Ewald DA, Ungar B, et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. *J Allergy Clin Immunol.* 2015;135(1):153-163.
62. Ewald DA, Malajian D, Krueger JG, et al. Meta-analysis derived atopic dermatitis (MADAD) transcriptome defines a robust AD signature highlighting the involvement of atherosclerosis and lipid metabolism pathways. *BMC Med Genomics.* 2015;8:60.
63. Suarez-Farinas M, Ungar B, Correa da Rosa J, et al. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. *J Allergy Clin Immunol.* 2015;135(5):1218-1227.
64. Akiyama T, Niyonsaba F, Kiatsurayanon C, et al. The human cathelicidin LL-37 host defense peptide upregulates tight junction-related proteins and increases human epidermal keratinocyte barrier function. *J Innate Immun.* 2014;6(6):739-753.
65. Batista DI, Perez L, Orfali RL, et al. Profile of skin barrier proteins (filaggrin, claudins 1 and 4) and Th1/Th2/Th17 cytokines in adults with atopic dermatitis. *J Eur Acad Dermatol Venereol.* 2015;29(6):1091-1095.
66. Thijs JL, Strickland I, Bruijnzeel-Koomen C, et al. Serum biomarker profiles suggest that atopic dermatitis is a systemic disease. *J Allergy Clin Immunol.* 2018;141(4):1523-1526.
67. McCormick SM, Heller NM. Commentary: IL-4 and IL-13 receptors and signaling. *Cytokine.* 2015;75(1):38-50.
68. Sehra S, Yao Y, Howell MD, et al. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. *J Immunol.* 2010;184(6):3186-3190.
69. Zheng T, Oh MH, Oh SY, Schroeder JT, Glick AB, Zhu Z. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. *J Invest Dermatol.* 2009;129(3):742-751.
70. Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. *J Allergy Clin Immunol.* 2007;120(1):150-155.
71. Kim BE, Leung DY, Boguniewicz M, Howell MD. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. *Clin Immunol.* 2008;126(3):332-337.
72. Oh MH, Oh SY, Yu J, et al. IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. *J Immunol.* 2011;186(12):7232-7242.

73. Oetjen LK, Mack MR, Feng J, et al. Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch. *Cell*. 2017;171(1):217-228.e213.
74. Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1. *J Allergy Clin Immunol*. 2014;133(2):448-460.
75. Tazawa T, Sugiura H, Sugiura Y, Uehara M. Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis. *Arch Dermatol Res*. 2004;295(11):459-464.
76. Beck LA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. *N Engl J Med*. 2014;371(2):130-139.
77. Hamilton J, Hamon S, Simpson E, et al. The effect of dupilumab on biomarkers in a randomized phase 2b clinical trial in adults with moderate-to-severe atopic dermatitis. *J Invest Dermatol*. Vol 1362016:S224.
78. Hamilton JD, Suarez-Farinas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. *J Allergy Clin Immunol*. 2014;134(6):1293-1300.
79. Popovic B, Breed J, Rees DG, et al. Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Ralpha1 and IL-13Ralpha2. *J Mol Biol*. 2017;429(2):208-219.
80. Chandriani S, DePianto DJ, N'Diaye EN, et al. Endogenously expressed IL-13Ralpha2 attenuates IL-13-mediated responses but does not activate signaling in human lung fibroblasts. *J Immunol*. 2014;193(1):111-119.
81. Kasaian MT, Raible D, Marquette K, et al. IL-13 antibodies influence IL-13 clearance in humans by modulating scavenger activity of IL-13Ralpha2. *J Immunol*. 2011;187(1):561-569.
82. Ultsch M, Bevers J, Nakamura G, et al. Structural basis of signaling blockade by anti-IL-13 antibody Lebrikizumab. *J Mol Biol*. 2013;425(8):1330-1339.
83. Tiwari A, Kasaian M, Heatherington AC, Jones HM, Hua F. A mechanistic PK/PD model for two anti-IL13 antibodies explains the difference in total IL-13 accumulation observed in clinical studies. *MAbs*. 2016;8(5):983-990.
84. Dupilumab (Dupixent) [package insert]. Sanofi and Regeneron Pharmaceuticals, Inc. 2017.
85. Wollenberg A, Howell MD, Guttman-Yassky E, et al. Treatment of Atopic Dermatitis with Tralokinumab, an Anti-IL-13 Monoclonal Antibody. *J Allergy Clin Immunol*. 2018.
86. Braddock M, Hanania NA, Sharafkhaneh A, Colice G, Carlsson M. Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review. *Drug Saf*. 2018;41(5):489-509.
87. Snast I, Reiter O, Hodak E, Friedland R, Mimouni D, Leshem YA. Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis. *Am J Clin Dermatol*. 2018;19(2):145-165.
88. Guttman-Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. *J Am Acad Dermatol*. 2018.
89. Gisondi P, Girolomoni G. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis. *Drug Des Devel Ther*. 2016;10:1763-1770.
90. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. *J Am Acad Dermatol*. 2016;75(3):494-503.e496.
91. Garmhausen D, Hagemann T, Bieber T, et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. *Allergy*. 2013;68(4):498-506.
92. Schmid-Grendelmeier P, Simon D, Simon HU, Akdis CA, Wuthrich B. Epidemiology, clinical features, and immunology of the "intrinsic" (non-IgE-mediated) type of atopic dermatitis (constitutional dermatitis). *Allergy*. 2001;56(9):841-849.
93. Park JH, Choi YL, Namkung JH, et al. Characteristics of extrinsic vs. intrinsic atopic dermatitis in infancy: correlations with laboratory variables. *Br J Dermatol*. 2006;155(4):778-783.
94. Paternoster L, Savenije OEM, Heron J, et al. Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts. *J Allergy Clin Immunol*. 2018;141(3):964-971.

95. Thijs JL, Strickland I, Bruijnzeel-Koomen C, et al. Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis. *J Allergy Clin Immunol*. 2017;140(3):730-737.
96. Muraro A, Lemanske RF, Jr., Hellings PW, et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. *J Allergy Clin Immunol*. 2016;137(5):1347-1358.
97. Bieber T, D'Erme AM, Akdis CA, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? *J Allergy Clin Immunol*. 2017;139(4S):S58-S64.
98. Kim HS, Kim JH, Seo YM, et al. Eosinophil-derived neurotoxin as a biomarker for disease severity and relapse in recalcitrant atopic dermatitis. *Ann Allergy Asthma Immunol*. 2017;119(5):441-445.
99. Nygaard U, Hvid M, Johansen C, et al. TSLP, IL-31, IL-33 and sST2 are new biomarkers in endophenotypic profiling of adult and childhood atopic dermatitis. *J Eur Acad Dermatol Venereol*. 2016;30(11):1930-1938.
100. Thijs JL, de Bruin-Weller MS, Hijnen D. Current and Future Biomarkers in Atopic Dermatitis. *Immunol Allergy Clin North Am*. 2017;37(1):51-61.
101. Guttman-Yassky E, Krueger JG, Lebwohl MG. Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment. *Exp Dermatol*. 2018;27(4):409-417.
102. Guttman-Yassky E, Lowes MA, Fuentes-Duculan J, et al. Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis. *J Allergy Clin Immunol*. 2007;119(5):1210-1217.
103. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. *N Engl J Med*. 2011;365(12):1088-1098.
104. Khattri S, Shemer A, Rozenblit M, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. *J Allergy Clin Immunol*. 2014;133(6):1626-1634.
105. Brunner PM, Khattri S, Garcet S, et al. A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis. *J Allergy Clin Immunol*. 2016;138(1):169-178.
106. Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in atopic dermatitis patients. *J Allergy Clin Immunol*. 2018.
107. Guttman-Yassky E, Brunner PM, Neumann AU, et al. Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. *J Am Acad Dermatol*. 2018;78(5):872-881.e876.
108. Guttman-Yassky E, Ungar B, Malik K, et al. Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis. *J Allergy Clin Immunol*. 2017;140(4):1032-1042.e1013.
109. Suarez-Farinas M, Gittler JK, Shemer A, Cardinale I, Krueger JG, Guttman-Yassky E. Residual genomic signature of atopic dermatitis despite clinical resolution with narrow-band UVB. *J Allergy Clin Immunol*. 2013;131(2):577-579.
110. Brunner PM, Pavel AB, Khattri S, et al. Baseline IL-22 expression in atopic dermatitis patients stratifies tissue responses to fezakinumab. *J Allergy Clin Immunol*. 2018 [In Press].
111. Cabanillas B, Brehler AC, Novak N. Atopic dermatitis phenotypes and the need for personalized medicine. *Curr Opin Allergy Clin Immunol*. 2017;17(4):309-315.
112. Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. *Immunotherapy*. 2015;7(10):1043-1058.
113. Thijs JL, Drylewicz J, Fiechter R, et al. EASI p-EASI: Utilizing a combination of serum biomarkers offers an objective measurement tool for disease severity in atopic dermatitis patients. *J Allergy Clin Immunol*. 2017;140(6):1703-1705.

114. Rozenblit M, Suarez-Farinas M, Shemer A, et al. Residual genomic profile after cyclosporine treatment may offer insights into atopic dermatitis reoccurrence. *J Allergy Clin Immunol*. 2014;134(4):955-957.
115. Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. *J Clin Invest*. 1994;94(2):870-876.
116. Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis of transgenic mice results in a pruritic inflammatory skin disease: an experimental animal model to study atopic dermatitis. *J Invest Dermatol*. 2001;117(4):977-983.
117. Hamid Q, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DY. In vivo expression of IL-12 and IL-13 in atopic dermatitis. *J Allergy Clin Immunol*. 1996;98(1):225-231.
118. Brunner PM, Israel A, Zhang N, et al. Early-onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22-centered inflammation and lipid alterations. *J Allergy Clin Immunol*. 2018;141(6):2094-2106.
119. Sanyal RD, Pavel AB, Glickman J, et al. Atopic dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17 attenuation. *Ann Allergy Asthma Immunol*. 2018.
120. Kim BS, Siracusa MC, Saenz SA, et al. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. *Sci Transl Med*. 2013;5(170):170ra116.
121. Salimi M, Barlow JL, Saunders SP, et al. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. *J Exp Med*. 2013;210(13):2939-2950.
122. Fujita H, Shemer A, Suarez-Farinas M, et al. Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets. *J Allergy Clin Immunol*. 2011;128(3):574-582 e571-512.
123. Bao K, Reinhardt RL. The differential expression of IL-4 and IL-13 and its impact on type-2 immunity. *Cytokine*. 2015;75(1):25-37.
124. Ying S, Humbert M, Barkans J, et al. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. *J Immunol*. 1997;158(7):3539-3544.
125. Gessner A, Mohrs K, Mohrs M. Mast cells, basophils, and eosinophils acquire constitutive IL-4 and IL-13 transcripts during lineage differentiation that are sufficient for rapid cytokine production. *J Immunol*. 2005;174(2):1063-1072.
126. Toru H, Pawankar R, Ra C, Yata J, Nakahata T. Human mast cells produce IL-13 by high-affinity IgE receptor cross-linking: enhanced IL-13 production by IL-4-primed human mast cells. *J Allergy Clin Immunol*. 1998;102(3):491-502.
127. Akbari O, Stock P, Meyer E, et al. Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity. *Nat Med*. 2003;9(5):582-588.
128. Hijnen D, Knol EF, Gent YY, et al. CD8(+) T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN-gamma, IL-13, IL-17, and IL-22. *J Invest Dermatol*. 2013;133(4):973-979.
129. Burd PR, Thompson WC, Max EE, Mills FC. Activated mast cells produce interleukin 13. *J Exp Med*. 1995;181(4):1373-1380.
130. Li H, Sim TC, Alam R. IL-13 released by and localized in human basophils. *J Immunol*. 1996;156(12):4833-4838.
131. Schmid-Grendelmeier P, Altnauer F, Fischer B, et al. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. *J Immunol*. 2002;169(2):1021-1027.
132. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. *N Engl J Med*. 2016;375(24):2335-2348.
133. Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. *Lancet*. 2017;389(10086):2287-2303.
134. Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). *J Am Acad Dermatol*. 2018;78(5):863-871 e811.

135. Toda M, Leung DY, Molet S, et al. Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. *J Allergy Clin Immunol*. 2003;111(4):875-881.
136. Koga C, Kabashima K, Shiraishi N, Kobayashi M, Tokura Y. Possible pathogenic role of Th17 cells for atopic dermatitis. *J Invest Dermatol*. 2008;128(11):2625-2630.
137. Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. *Nat Immunol*. 2011;12(12):1159-1166.
138. Vandeghinste N, Klattig J, Jagerschmidt C, et al. Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis. *J Invest Dermatol*. 2018;138(7):1555-1563.
139. Thaci D CM, Rojkovich B, et al. MOR106, an anti-IL-17C mAb, a potential new approach for treatment of moderate-to-severe atopic dermatitis: Phase 1 study. *Presented at the American Academy of Dermatology 2018 Meeting, San Diego, CA, Feb 16-20, 2018*. 2018.
140. Suarez-Farinas M, Ungar B, Noda S, et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. *J Allergy Clin Immunol*. 2015;136(5):1277-1287.
141. Khattri S, Brunner PM, Garcet S, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. *Exp Dermatol*. 2017;26(1):28-35.
142. Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: End of the drought? *J Allergy Clin Immunol*. 2017;140(3):633-643.
143. Lou H, Lu J, Choi EB, et al. Expression of IL-22 in the Skin Causes Th2-Biased Immunity, Epidermal Barrier Dysfunction, and Pruritus via Stimulating Epithelial Th2 Cytokines and the GRP Pathway. *J Immunol*. 2017;198(7):2543-2555.
144. Dillon SR, Sprecher C, Hammond A, et al. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. *Nat Immunol*. 2004;5(7):752-760.
145. Feld M, Garcia R, Buddenkotte J, et al. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. *J Allergy Clin Immunol*. 2016;138(2):500-508.e524.
146. Hanel KH, Pfaff CM, Cornelissen C, et al. Control of the Physical and Antimicrobial Skin Barrier by an IL-31-IL-1 Signaling Network. *J Immunol*. 2016;196(8):3233-3244.
147. Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. *J Allergy Clin Immunol*. 2018.
148. Seltmann J, Roesner LM, von Hesler FW, Wittmann M, Werfel T. IL-33 impacts on the skin barrier by downregulating the expression of filaggrin. *J Allergy Clin Immunol*. 2015;135(6):1659-1661.e1654.
149. Ogg GS. Proof-of-concept phase-2a clinical trial of ANB020 (anti-IL-33 antibody) in the treatment of moderate-to-severe adult atopic dermatitis. *Presented at the European Academy of Allergy and Clinical Immunology Congress, May 26-30, Munich, Germany*. 2018.
150. Nakajima S, Igyarto BZ, Honda T, et al. Langerhans cells are critical in epicutaneous sensitization with protein antigen via thymic stromal lymphopoietin receptor signaling. *J Allergy Clin Immunol*. 2012;129(4):1048-1055.e1046.
151. Wilson SR, The L, Batia LM, et al. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch. *Cell*. 2013;155(2):285-295.
152. Jariwala SP, Abrams E, Benson A, Fodeman J, Zheng T. The role of thymic stromal lymphopoietin in the immunopathogenesis of atopic dermatitis. *Clin Exp Allergy*. 2011;41(11):1515-1520.
153. Anon. AstraZeneca PLC Year-to-Date and Q3 2017 Results. Available at [https://www.astrazenecacom/content/dam/az/PDF/2017/Q3/Year-to-date\\_and\\_Q3\\_2017\\_Results\\_Announcementpdf](https://www.astrazenecacom/content/dam/az/PDF/2017/Q3/Year-to-date_and_Q3_2017_Results_Announcementpdf) (accessed September 5, 2018).
154. Ilves T, Harvima IT. OX40 ligand and OX40 are increased in atopic dermatitis lesions but do not correlate with clinical severity. *J Eur Acad Dermatol Venereol*. 2013;27(2):e197-205.
155. Croft M. The role of TNF superfamily members in T-cell function and diseases. *Nat Rev Immunol*. 2009;9(4):271-285.
156. Lathrop SK, Huddleston CA, Dullforce PA, Montfort MJ, Weinberg AD, Parker DC. A signal through OX40 (CD134) allows anergic, autoreactive T cells to acquire effector cell functions. *J Immunol*. 2004;172(11):6735-6743.

157. Papp KA, Gooderham MJ, Girard G, Raman M, Strout V. Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis. *J Eur Acad Dermatol Venereol*. 2017;31(8):1324-1332.
158. Results from a randomized, double-blind, placebo-controlled, exploratory, multicenter study of GBR 830 in adult patients with moderate-to-severe atopic dermatitis. *Journal of the American Academy of Dermatology*. 2018;79(3):AB245.
159. Chan S, Cornelius V, Chen T, et al. Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT): the role of anti-IgE in severe paediatric eczema: study protocol for a randomised controlled trial. *Trials*. 2017;18(1):136.
160. Wang HH, Li YC, Huang YC. Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis. *J Allergy Clin Immunol*. 2016;138(6):1719-1722 e1711.
161. Holm JG, Agner T, Sand C, Thomsen SF. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. *IF 1415*. 2017;56(1):18-26.

## FIGURE LEGENDS

**Figure 1. Type 2 Receptor for IL-4 and IL-13.** (A) The interleukin-4 type 2 receptor complex, comprised of IL-4R $\alpha$  and IL-13R $\alpha$ 1 subunits. (B) Binding of IL-4 to IL-4R $\alpha$  induces receptor dimerization with IL-13R $\alpha$ 1 and signal transduction via the JAK/STAT pathway, leading to increased transcription of genes associated with inflammation. (C) In a similar way, binding of IL-13 to IL-13R $\alpha$ 1 also induces dimerization with IL-4R $\alpha$ , signal transduction, and increased pro-inflammatory gene expression. IL, interleukin; IL-4R $\alpha$ , IL-4 receptor alpha; IL-13R $\alpha$ , IL-13 receptor alpha.

**Figure 2. Mechanism of Action for Biologics Targeting the IL-4 and/or IL-13 Pathways.** IL, interleukin; IL-4R $\alpha$ , IL-4 receptor alpha; IL-13R $\alpha$ , IL-13 receptor alpha.

**Table 1. Key Characteristics of AD: Acute and Chronic Disease, Non-Lesional and Lesional Skin**

| Characteristic                                                            | Acute Disease <sup>a</sup>                                                                                                                                                                                                                                    | Chronic Disease <sup>b</sup>                                                                                          |
|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|
| <b>Type 2 pathway activation and related cytokines/chemokines</b>         | Increased (IL-4, IL-13, IL-31) <sup>28,44,69,75,115-117</sup>                                                                                                                                                                                                 | Intensified (IL-5, IL-13, IL-31, IL-10, CCL5, CCL13, CCL18); Mixed results for IL-4 <sup>28,33,44,69,75,115-117</sup> |
| <b>Type 22 pathway activation and related cytokines</b>                   | Increased (IL-22) <sup>28,44</sup>                                                                                                                                                                                                                            | Intensified (IL-22, IL-32) <sup>28,44</sup>                                                                           |
| <b>Type 1 pathway activation and related cytokines/chemokines</b>         | Slightly increased (IFN $\gamma$ , MX1, IL-1 $\beta$ , CXCL9-11), but not in all phenotypes <sup>32,44,51,118,119</sup>                                                                                                                                       | Significantly increased <sup>44</sup>                                                                                 |
| <b>Type 17 pathway activation and related cytokines</b>                   | Slightly increased (IL-17, IL-23p19, IL-23p40) <sup>44</sup>                                                                                                                                                                                                  | Magnitude of activation is similar to that observed in acute disease <sup>44</sup>                                    |
| <b>Immune cell infiltration</b>                                           | Increased (T cells, ILC2s, DCs [mature and IDECs], and other myeloid cells) <sup>44,120,121</sup>                                                                                                                                                             | Intensified <sup>44</sup>                                                                                             |
| <b>Epidermal changes</b>                                                  | Increased hyperplasia, thickness, and proliferation markers (Ki67, K16) as well as the IL-22-regulated S100A7-9 and S100A12 that mark epidermal hyperplasia; <sup>44</sup> reduced epidermal barrier proteins (involucrin, loricrin, filaggrin) <sup>44</sup> | Intensified <sup>44</sup>                                                                                             |
| <b>Reduced expression of terminal differentiation proteins and lipids</b> | Reduced expression of FLG, LOR, PPL, and other differentiation proteins and significant lipid aberrations <sup>44,61-63</sup>                                                                                                                                 | Intensified <sup>44</sup>                                                                                             |

| Characteristic                                        | Non-Lesional Skin                                                                                                                | Lesional Skin                                                                                                                                                                                                                 |
|-------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Inflammatory cytokine and chemokine profile</b>    | Type 2 cytokines (IL-13, CCL18, CCL22), MX1, IL-22, and S100A7 <sup>28,47</sup>                                                  | MMP12, type 2 cytokines (IL-13, CCL11, CCL17, CCL18, CCL22), type 1 cytokines (IFN $\gamma$ , CXCL10), IL-22, type 17 cytokines (IL-23p19, IL-12/23p40, CXCL1), PI3/elafin, and S100 cytokine family members <sup>28,47</sup> |
| <b>Immune cell infiltration</b>                       | Increased (T cells, DCs [mature and IDECs], and other myeloid cells) <sup>28,47,122</sup>                                        | Intensified <sup>28,47</sup>                                                                                                                                                                                                  |
| <b>Epidermal changes</b>                              | Increased hyperplasia, thickness, and epidermal proliferation markers (Ki67, K16), expression of S100As <sup>28,47</sup>         | Intensified <sup>28,47</sup>                                                                                                                                                                                                  |
| <b>Expression of terminal differentiation markers</b> | Downregulated and inversely correlated with disease severity ( <i>IVL</i> , <i>LOR</i> , <i>PPL</i> , <i>FLG</i> ) <sup>28</sup> | Magnitude of change is similar to that observed in non-lesional skin <sup>28</sup>                                                                                                                                            |

<sup>a</sup> Acute lesions compared with non-lesional skin

<sup>b</sup> Chronic lesions compared with acute lesions; “intensified”, as it relates to changes, indicates substantial differences that are not always statistically significant

AD, atopic dermatitis; CCL, C-C motif chemokine ligand; CXCL, C-X-C motif chemokine ligand; DC, dendritic cell; FLG, filaggrin; IDEC, inflammatory dendritic epidermal cells; IFN, interferon; IL, interleukin; ILC, innate lymphoid cell; IVL, involucrin; K16, keratin 16; LOR, loricrin; MMP, matrix metalloproteinase; PPL, periplakin.

**Table 2. Key Similarities and Differences Between IL-4 and IL-13**

| Characteristic                       | IL-4                                                                                                                                                | IL-13                                                                                                  |
|--------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------|
| <b>Expression in AD lesions</b>      | Mixed results for patient lesions <sup>75,115</sup>                                                                                                 | Increased in acute and chronic patient lesions <sup>69,75,115,117</sup>                                |
| <b>Signaling</b>                     | Both type 1 and type 2 heterodimeric receptors:<br>(1) IL-4R $\alpha$ and $\gamma$ c and (2) IL-4R $\alpha$ and IL-13R $\alpha$ 1 <sup>67,123</sup> | Type 2 heterodimeric receptor only:<br>IL-4R $\alpha$ and IL-13R $\alpha$ 1 <sup>67,123</sup>          |
| <b>Th2 cell differentiation</b>      | Stimulate and promote development <sup>68,123</sup>                                                                                                 | Stimulate and promote development <sup>123</sup>                                                       |
| <b>Tissue inflammation</b>           | Deficiency protects against AD in mouse model <sup>68</sup>                                                                                         | Expression associated with chronic inflammatory phenotype in mouse model <sup>69</sup>                 |
| <b>Produced by cells</b>             | CD4+ and CD8+ T cells, mast cells, basophils, eosinophils <sup>123-127</sup>                                                                        | CD4+ and CD8+ T cells, ILCs, mast cells, basophils, eosinophils, iNKTs <sup>127-131</sup>              |
| <b>IgE production</b>                | Activates B cells, augments antibody production and regulates IgE class switching <sup>33</sup>                                                     |                                                                                                        |
| <b>Epidermal barrier dysfunction</b> | Promote keratinocyte damage and reduce filaggrin, loricrin, and involucrin expression <sup>33,70</sup>                                              | Promote keratinocyte damage and reduce filaggrin, loricrin, and involucrin expression <sup>33,70</sup> |
| <b>Tissue fibrosis</b>               | No major role <sup>67</sup>                                                                                                                         | Promotes fibrotic skin remodeling <sup>67,72</sup>                                                     |
| <b>Characteristics of detection</b>  | IL-4 protein and mRNA are rarely detected                                                                                                           | IL-13 is commonly detected (eg, in circulation, IL-13-positive T cells)                                |
| <b>Murine Models</b>                 | Transgenic overexpression of IL-4 <sup>116</sup> or IL-13 <sup>69</sup> in epidermis of mice results in AD-like phenotype                           |                                                                                                        |

AD, atopic dermatitis; IgE, immunoglobulin E; IL, interleukin; IL-4R $\alpha$ , IL-4 receptor alpha; IL-13R $\alpha$ 1, IL-13 receptor alpha 1; ILC, innate lymphoid cell; iNKT, invariant natural killer cell; mRNA, messenger ribonucleic acid; Th2, T helper cell type 2;  $\gamma$ c, common gamma chain.

**Table 3. Clinical Trial Design for Completed Trials of Biologics Targeting IL-4 and IL-13**

|                                               | <b>Dupilumab</b>                                                                                                                                                         | <b>Lebrikizumab</b>                                                                                                                                                               | <b>Tralokinumab</b>      |
|-----------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
| <b>Clinical Development Status for M/S AD</b> | Approved in adults as monotherapy or adjunct therapy                                                                                                                     | Clinical studies ongoing                                                                                                                                                          | Clinical studies ongoing |
| <b>Key Clinical Trial Design Summary</b>      |                                                                                                                                                                          |                                                                                                                                                                                   |                          |
| <b>MONOTHERAPY</b>                            |                                                                                                                                                                          |                                                                                                                                                                                   |                          |
| <b>Trial Name</b>                             | SOLO 1 and SOLO 2: Ph3 monotherapy in adult M/S AD vs PBO [NCT02277743; NCT02277769] <sup>76,132</sup>                                                                   | ARBAN: Ph2 OL, monotherapy study in adult M/S AD vs TCS BID [NCT02465606]                                                                                                         | NA                       |
| <b>Trial Design</b>                           |                                                                                                                                                                          |                                                                                                                                                                                   |                          |
| <b>Duration</b>                               | 16 wks                                                                                                                                                                   | 12 wks (TCS during run-in followed by TCS withdrawal in tx group)                                                                                                                 |                          |
| <b>Dosing</b>                                 | 300mg Q2W                                                                                                                                                                | 125mg Q4W                                                                                                                                                                         |                          |
| <b>Sample Size</b>                            | N=1379 (SOLO 1 and 2)                                                                                                                                                    | N=55                                                                                                                                                                              |                          |
| <b>Age</b>                                    | ≥18 yrs                                                                                                                                                                  | 18-75 yrs                                                                                                                                                                         |                          |
| <b>Key Inclusion/Exclusion</b>                | <ul style="list-style-type: none"> <li>Chronic AD ≥3 years</li> <li>IGA ≥3 (5-pt scale)</li> <li>EASI ≥16</li> <li>BSA affected ≥10%</li> <li>Pruritus NRS ≥3</li> </ul> | <ul style="list-style-type: none"> <li>M/S AD ≥1 year</li> <li>IGA ≥3 (5-pt scale)</li> <li>EASI ≥14</li> <li>BSA affected ≥10%</li> <li>Pruritus VAS (from SCORAD) ≥3</li> </ul> |                          |
| <b>Primary Endpoints</b>                      | IGA 0/1 (%) + ≥2 pt reduction, wk 16                                                                                                                                     | TEAE (%)                                                                                                                                                                          |                          |

| COMBINATION THERAPY STUDIES    |                                                                                                                                                                                    |                                                                                                                                                                                             |                                                                                                                                                                             |
|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Trial Name</b>              | CHRONOS: Ph3 R, DB study + TCS vs PBO + TCS [NCT02260986] <sup>133</sup>                                                                                                           | TREBLE Ph2: R, DB study + TCS [NCT02340234] <sup>134</sup>                                                                                                                                  | Ph2 study in adults with M/S AD [NCT02347176] <sup>85</sup>                                                                                                                 |
| <b>Trial Design</b>            |                                                                                                                                                                                    |                                                                                                                                                                                             |                                                                                                                                                                             |
| <b>Duration</b>                | 52 wks (BID moisturizer and concomitant TCS or TCI rescue [topical, systemic, or phototherapy] permitted after wk 2)                                                               | 12 wks (TCS during run-in followed by TCS BID)                                                                                                                                              | 12 wks (2-wk TCS run-in period with TCS)                                                                                                                                    |
| <b>Dosing</b>                  | 300mg Q2W                                                                                                                                                                          | 125mg SD, 250mg SD, 125mg Q4W                                                                                                                                                               | 45mg Q2W, 150mg Q2W, 300mg Q2W                                                                                                                                              |
| <b>Sample Size</b>             | N=740                                                                                                                                                                              | N=209                                                                                                                                                                                       | N=204                                                                                                                                                                       |
| <b>Age</b>                     | ≥18 yrs                                                                                                                                                                            | 18-75 yrs                                                                                                                                                                                   | 18-75 yrs                                                                                                                                                                   |
| <b>Key Inclusion/Exclusion</b> | <ul style="list-style-type: none"> <li>• Chronic AD ≥3 years</li> <li>• IGA ≥3 (5-pt scale)</li> <li>• EASI ≥16</li> <li>• BSA affected ≥10%</li> <li>• Pruritus NRS ≥3</li> </ul> | <ul style="list-style-type: none"> <li>• M/S AD ≥1 year</li> <li>• IGA ≥3 (5-pt scale)</li> <li>• EASI ≥14</li> <li>• BSA affected ≥10%</li> <li>• Pruritus VAS (from SCORAD) ≥3</li> </ul> | <ul style="list-style-type: none"> <li>• M/S AD &gt;1 year</li> <li>• IGA ≥3 (6-pt scale)</li> <li>• EASI ≥12</li> <li>• BSA affected ≥10%</li> <li>• SCORAD ≥25</li> </ul> |
| <b>Primary Endpoints</b>       | EASI 75 (%) and IGA 0/1 (%) at wk 16                                                                                                                                               | EASI 50 (%) at wk 12                                                                                                                                                                        | EASI 50 (%) at wk 12<br>IGA 0/1 (%) + ≥2 pt reduction, wk 12                                                                                                                |

AD, atopic dermatitis; BID, twice daily; BSA, body surface area; DB, double-blind; EASI, Eczema Area and Severity Index; EASI 50, ≥50% improvement in EASI from baseline; EASI 75, ≥75% improvement in EASI from baseline; IGA, investigator's global assessment; IGA 0/1, 'clear'/'almost clear' with ≥2-point improvement; IL, interleukin; M/S, moderate-to-severe; NA, not available; NRS, numeric rating scale; OL, open-label; PBO, placebo; Ph, phase; pt, point; Q2W, every 2 weeks; Q4W, every 4 weeks; R, randomized; SCORAD, Scoring of Atopic Dermatitis; SD, single dose; TCI, topical calcineurin inhibitor; TCS, topical corticosteroids; TEAE, treatment-emergent adverse event; VAS, visual analogue scale; wk, week; yrs, years.

**Table 4. Other Key Biologics in Development for AD**

| Target                 | Pathophysiological Role                                                                                                                                                                                                                                            | Pipeline Activity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Comments                                                                                                                                                                                |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>IL-17A</b>          | Expression of the key Th17-related cytokine, IL-17A, is increased in acute AD lesions, along with infiltration of IL-17 positive cells into these lesions <sup>135,136</sup>                                                                                       | Secukinumab: a human IgG1κ, anti-IL-17A monoclonal antibody administrated subcutaneously <ul style="list-style-type: none"> <li>Phase 2 (moderate-to-severe AD) <ul style="list-style-type: none"> <li>A 52-week pilot study (NCT02594098) is completed</li> <li>A 16-week randomized controlled trial (Secu_in_AD [NCT03568136]) is underway</li> </ul> </li> </ul>                                                                                                                                                                    | Secukinumab is FDA approved for moderate/severe plaque psoriasis, active psoriatic arthritis, and ankylosing spondylitis; results in AD trials have not yet been reported               |
| <b>IL-17C</b>          | Member of IL-17 family of cytokines that is produced at high levels in AD, induced by bacterial stimuli, and may be involved in a pathogenic amplification loop that links the cutaneous microbiome with induction of IL-17-driven inflammation <sup>137,138</sup> | MOR106: a human IgG1, anti-IL-17C monoclonal antibody administered intravenously <ul style="list-style-type: none"> <li>Phase 2 (moderate-to-severe AD)</li> <li>Under investigation in a randomized controlled trial (NCT03568071)</li> </ul>                                                                                                                                                                                                                                                                                          | In a phase 1 study (NCT02739009), 83% of patients in the high dose group achieved $\geq$ EASI 50 by week 4 <sup>139</sup>                                                               |
| <b>IL-12 and IL-23</b> | IL-12 and IL-23 are upregulated in AD lesions and drive differentiation of Th1 and Th17 cells, respectively <sup>140</sup>                                                                                                                                         | Ustekinumab: a human IgG1κ, anti-IL-12/IL-23p40 monoclonal antibody that inhibits type 1 and type 17 immune responses through the targeted inhibition of the p40 subunit that is shared by these inflammatory cytokines <sup>45</sup> <ul style="list-style-type: none"> <li>Phase 2 (moderate-to-severe AD) <ul style="list-style-type: none"> <li>Despite completion of a 16-week, phase 2 study (NCT01806662) in adults with moderate-to-severe AD, further clinical development is unclear<sup>141,142</sup></li> </ul> </li> </ul> | Non-significant improvements in SCORAD 50, the primary endpoint, were noted; effects may have been obscured by background TCS effects or insufficient ustekinumab dosing <sup>141</sup> |
| <b>IL-22</b>           | The key type 22 cytokine, IL-22, contributes to epidermal hyperplasia and inhibits keratinocyte differentiation <sup>58,143</sup>                                                                                                                                  | Fezakinumab: an intravenous, human IgG1λ, anti-IL-22 monoclonal antibody <ul style="list-style-type: none"> <li>Phase 2 (moderate-to-severe AD) <ul style="list-style-type: none"> <li>A phase 2a randomized controlled trial</li> </ul> </li> </ul>                                                                                                                                                                                                                                                                                    | The primary efficacy endpoint, decline in SCORAD index at week 12, non-significantly favored fezakinumab (13.8 vs 8.0; $P=0.134$ ), but the improvement                                 |

|                                                     |                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                         |
|-----------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                     |                                                                                                                                                                                                                                                                            | (NCT01941537) in adults with moderate-to-severe AD; development of the biologic is ongoing, though no phase 3 trials are planned as of February 2019 <sup>142</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | was significant in the severe AD subset (21.6 vs 9.6; $P=0.010$ ) <sup>107</sup>                                                                                                                        |
| <b>IL-31</b>                                        | Produced by Th2 cells and mature dendritic cells and functions to evoke itch; <sup>74,144,145</sup> also alters expression of barrier proteins <sup>146</sup>                                                                                                              | Nemolizumab: a humanized IgG2 $\kappa$ , anti-IL-31R $\alpha$ monoclonal antibody that mitigates IL-31-dependent processes by antagonizing its cognate receptor <ul style="list-style-type: none"> <li>Phase 2 (moderate-to-severe AD) <ul style="list-style-type: none"> <li>A two-part, phase 2b randomized controlled trial (NCT01986933) in adults inadequately controlled by topical treatments<sup>147</sup> and a randomized controlled trial in adults receiving concomitant topical corticosteroids (NCT03100344) have completed</li> </ul> </li> </ul>                                                                             | In part B of this study, improvements in pruritus VAS were maintained/increased at week 64, and change in EASI score ranged from -68.5% to -78.9% in the various nemolizumab dosing arms <sup>147</sup> |
| <b>IL-33</b>                                        | An IL-1 family member which enhances type 2 responses through the induction of IL-5 and IL-13 in ILC2, type 1 responses through induction of IFN $\gamma$ , and also contributes to epidermal barrier dysfunction by downregulation of filaggrin expression <sup>148</sup> | ANB020: a humanized IgG1, anti-IL-33 monoclonal antibody <ul style="list-style-type: none"> <li>Phase 2 (moderate-to-severe AD) <ul style="list-style-type: none"> <li>Completed phase 2a proof of concept trial in moderate-to-severe AD</li> <li>A phase 2b randomized controlled trial (ATLAS [NCT03533751]) is ongoing as of February 2019</li> </ul> </li> </ul> PF-06817024: an anti-IL-33 monoclonal antibody <ul style="list-style-type: none"> <li>Phase 1 (moderate-to-severe AD) <ul style="list-style-type: none"> <li>A phase 1 randomized controlled trial (NCT02743871) is ongoing as of February 2019</li> </ul> </li> </ul> | ANB020: In a phase 2a proof of concept trial, 12/12 patients achieved at least EASI 50 by day 57 <sup>149</sup><br><br>PF-0681724: No results have been reported to date                                |
| <b>Thymic stromal lymphopoietin (TSLP) receptor</b> | TSLP is highly expressed in skin epithelial cells in AD and has known roles in generating type 2 immune responses and inducing itch in AD <sup>142,150-152</sup> ; its cognate receptor, TSLPR, is expressed on multiple immune                                            | Tezepelumab: a human IgG2 $\lambda$ , anti-TSLP monoclonal antibody <ul style="list-style-type: none"> <li>Phase 2 (moderate-to-severe AD) <ul style="list-style-type: none"> <li>Completed phase 1 (NCT00757042) and phase 2a (ALLEVIAD [NCT02525094]) randomized controlled trials in adults with moderate-to-severe AD</li> <li>Development is ongoing, though no phase 3</li> </ul> </li> </ul>                                                                                                                                                                                                                                          | A company press release noted that tezepelumab did not meet statistical significance for the phase 2a primary efficacy endpoint (EASI 50); <sup>153</sup> no further results have been reported         |

|             |                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |                                                                                                                                                                                                                                                            |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|             | cells, including T cells, B cells, dendritic cells, mast cells, basophils, and eosinophils <sup>150</sup>                                                                                                                                                                                                                                                                                            | trials are planned as of February 2019 <sup>142</sup>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                                                                                                                                                                                                                                            |
| <b>OX40</b> | Expression of OX40, a tumor necrosis factor receptor family member, and its ligand OX40L is increased in AD lesions; <sup>154</sup> affects T cell proliferation, survival, and memory cell formation, <sup>155</sup> can cause autoreactive T cells to acquire pathogenic effector functions, <sup>156</sup> though no direct correlation with disease severity has been established <sup>154</sup> | <p>KHK4083: a fully human, non-fucosylated IgG1, anti-OX40 monoclonal antibody</p> <ul style="list-style-type: none"> <li>Phase 2 (moderate-to-severe AD) <ul style="list-style-type: none"> <li>Completed phase 1 open-label study (NCT03096223)<sup>157</sup></li> <li>Phase 2 randomized controlled trial in adults inadequately controlled by topical treatments is ongoing as of February 2019</li> </ul> </li> </ul> <p>GBR 830: a humanized anti-OX40 monoclonal antibody</p> <ul style="list-style-type: none"> <li>Phase 2 (moderate-to-severe AD) <ul style="list-style-type: none"> <li>Completed phase 2a randomized controlled trial (NCT02683928)</li> <li>Phase 2b dose-ranging study is ongoing as of February 2019 (NCT03568162)</li> </ul> </li> </ul> | <p>KHK4083: No information currently available</p> <p>GBR 830: 17/23 evaluable patients (74%) had a <math>\geq 50\%</math> reduction in EASI score at week 4; study not powered to detect differences between GBR 830 and placebo groups<sup>158</sup></p> |
| <b>IgE</b>  | Increased levels of serum immunoglobulin E (IgE) are commonly detected in AD patients, but its role in pathophysiology is not clear <sup>2</sup>                                                                                                                                                                                                                                                     | <p>Omalizumab: humanized IgG1<math>\kappa</math> monoclonal antibody</p> <ul style="list-style-type: none"> <li>Phase 4 (children with severe recalcitrant atopic eczema) <ul style="list-style-type: none"> <li>A phase 4 study (NCT02300701) is ongoing in children (ie, 4 to 19 years) with severe recalcitrant atopic eczema as of February 2019<sup>142,159</sup></li> </ul> </li> </ul>                                                                                                                                                                                                                                                                                                                                                                            | Two systematic reviews found clinical benefits for omalizumab in selected patients with AD; <sup>160,161</sup> results for NCT02300701 have not yet been reported                                                                                          |

AD, atopic dermatitis; EASI, Eczema Area and Severity Index; EASI 50,  $\geq 50\%$  improvement in EASI from baseline; FDA, Food and Drug Administration; IFN, interferon; IgG, immunoglobulin G; IL, interleukin; ILC, innate lymphoid cell; SCORAD, Scoring of Atopic Dermatitis; TCS, topical corticosteroids; Th, T helper cell; VAS, visual analogue scale.

